Home LiteratureArticle Details
PMID: 9540161 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Apoptosis by p53: mechanisms, regulation, and clinical implications.

Springer seminars in immunopathology ·Vol. 19 ·No. 3 ·1998-00-00 ·Pages 345-62

Sionov RV, Haupt Y

Abstract

暂无摘要

MeSH Terms
Apoptosis/genetics Genes, p53/physiology Humans
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Sionov R V
Lautenberg Center for General and Tumor Immunology, Hebrew University Hadassah Medical School, Jerusalem, Israel.
Haupt Y
References (103)
103 references, click to expand
  1. Identification of a novel p53 functional domain that is necessary for efficient growth suppression.
    Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15335-40 PMID: 8986812
  2. New insights into p53 function from structural studies.
    Oncogene. 1996 Apr 4;12(7):1379-85 PMID: 8622853
  3. Abrogation of wild-type p53 mediated growth-inhibition by nuclear exclusion.
    Oncogene. 1996 Apr 18;12(8):1755-65 PMID: 8622896
  4. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.
    EMBO J. 1996 Feb 15;15(4):827-38 PMID: 8631304
  5. Biological and clinical importance of the p53 tumor suppressor gene.
    Clin Chem. 1996 Jun;42(6 Pt 1):858-68 PMID: 8665676
  6. Cell type-specific inhibition of p53-mediated apoptosis by mdm2.
    EMBO J. 1996 Apr 1;15(7):1596-606 PMID: 8612583
  7. The cellular effects of E2F overexpression.
    Curr Top Microbiol Immunol. 1996;208:79-93 PMID: 8575214
  8. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells.
    Gynecol Oncol. 1996 Nov;63(2):219-27 PMID: 8910631
  9. p53, the cellular gatekeeper for growth and division.
    Cell. 1997 Feb 7;88(3):323-31 PMID: 9039259
  10. Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression.
    Br J Cancer. 1997;75(9):1295-301 PMID: 9155049
  11. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes.
    J Exp Med. 1997 Mar 3;185(5):833-41 PMID: 9120389
  12. Interaction between ATM protein and c-Abl in response to DNA damage.
    Nature. 1997 May 29;387(6632):520-3 PMID: 9168117
  13. Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2.
    Oncogene. 1997 Apr 17;14(15):1859-68 PMID: 9150392
  14. Essential role for p53-mediated transcription in E1A-induced apoptosis.
    Genes Dev. 1995 Sep 1;9(17):2184-92 PMID: 7657169
  15. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype.
    Science. 1997 Feb 14;275(5302):967-9 PMID: 9020077
  16. Life, death, and the pursuit of apoptosis.
    Genes Dev. 1996 Jan 1;10(1):1-15 PMID: 8557188
  17. p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells.
    Oncogene. 1997 Feb 27;14(8):929-35 PMID: 9050992
  18. Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro.
    Hum Gene Ther. 1997 Mar 1;8(4):467-75 PMID: 9054521
  19. Wilms' tumor 1-KTS isoforms induce p53-independent apoptosis that can be partially rescued by expression of the epidermal growth factor receptor or the insulin receptor.
    Cancer Res. 1997 Apr 1;57(7):1353-63 PMID: 9102224
  20. Antisense technology and prospects for therapy of viral infections and cancer.
    Mol Med Today. 1997 Jan;3(1):31-8 PMID: 9021740
  21. A novel p53 germline alteration identified in a late onset breast cancer kindred.
    Oncogene. 1996 Jul 18;13(2):407-11 PMID: 8710380
  22. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53.
    Cancer Res. 1995 Aug 15;55(16):3490-4 PMID: 7627952
  23. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis.
    Nat Med. 1996 Jan;2(1):72-9 PMID: 8564846
  24. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.
    Nat Med. 1996 Jul;2(7):811-4 PMID: 8673929
  25. The growth-inhibitory function of p53 is separable from transactivation, apoptosis and suppression of transformation by E1a and Ras.
    Oncogene. 1996 Sep 5;13(5):995-1007 PMID: 8806689
  26. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function.
    Mol Cell Biol. 1996 Sep;16(9):4952-60 PMID: 8756654
  27. p53 in growth control and neoplasia.
    Biochim Biophys Acta. 1996 Jun 7;1287(2-3):77-102 PMID: 8672531
  28. The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy.
    Immunol Today. 1996 Aug;17(8):354-6 PMID: 8783493
  29. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.
    Nature. 1995 Nov 9;378(6553):203-6 PMID: 7477326
  30. Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer.
    J Natl Cancer Inst. 1997 May 7;89(9):639-45 PMID: 9150188
  31. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.
    J Natl Cancer Inst. 1996 Jul 17;88(14):956-65 PMID: 8667426
  32. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis.
    Oncogene. 1995 May 18;10(10):2001-6 PMID: 7761100
  33. p53--integrating the complexity.
    J Pathol. 1996 Sep;180(1):1-5 PMID: 8943807
  34. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family.
    Oncogene. 1997 Apr 17;14(15):1869-74 PMID: 9150393
  35. p53 and ATM: cell cycle, cell death, and cancer.
    Adv Cancer Res. 1997;71:1-25 PMID: 9111862
  36. p53 as a target for anti-cancer immunotherapy.
    Mol Med Today. 1997 Apr;3(4):160-7 PMID: 9134529
  37. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis.
    Genes Dev. 1995 Sep 1;9(17):2143-56 PMID: 7657166
  38. Bax suppresses tumorigenesis and stimulates apoptosis in vivo.
    Nature. 1997 Feb 13;385(6617):637-40 PMID: 9024662
  39. A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis.
    EMBO J. 1997 Jul 16;16(14):4384-92 PMID: 9250682
  40. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein.
    Mol Cell Biol. 1996 May;16(5):2445-52 PMID: 8628312
  41. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis.
    EMBO J. 1996 Jul 15;15(14):3693-701 PMID: 8758936
  42. Activation of CPP32 and Mch3 alpha in wild-type p53-induced apoptosis.
    Biochem J. 1997 Feb 15;322 ( Pt 1):19-23 PMID: 9078237
  43. Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer.
    Br J Urol. 1997 Mar;79(3):373-7 PMID: 9117216
  44. Gene delivery into malignant cells in vivo by a conjugated adenovirus/DNA complex.
    Cancer Gene Ther. 1997 May-Jun;4(3):183-90 PMID: 9171937
  45. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer.
    J Thorac Cardiovasc Surg. 1996 Nov;112(5):1372-6; discussion 1376-7 PMID: 8911337
  46. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death.
    Nat Med. 1997 Mar;3(3):313-9 PMID: 9055859
  47. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells.
    Genes Dev. 1996 Oct 1;10(19):2438-51 PMID: 8843196
  48. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6.
    Nature. 1991 Jul 25;352(6333):345-7 PMID: 1852210
  49. Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase.
    Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1437-40 PMID: 9037071
  50. The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype.
    Ann N Y Acad Sci. 1995 Sep 30;768:111-28 PMID: 8526340
  51. Tumor suppressors: a developing role for p53?
    Curr Biol. 1997 Mar 1;7(3):R144-7 PMID: 9162475
  52. Clinical implications of the p53 gene.
    Annu Rev Med. 1996;47:285-301 PMID: 8712782
  53. T cells from baxalpha transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53.
    EMBO J. 1996 Mar 15;15(6):1221-30 PMID: 8635454
  54. The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal.
    Mol Cell Biol. 1997 Mar;17(3):1084-92 PMID: 9032235
  55. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis.
    Mol Cell Biol. 1996 Sep;16(9):4961-71 PMID: 8756655
  56. Identification of novel mdm2 binding peptides by phage display.
    Oncogene. 1996 Nov 21;13(10):2141-7 PMID: 8950981
  57. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression.
    Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2587-92 PMID: 9122239
  58. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.
    Genes Dev. 1994 May 15;8(10):1235-46 PMID: 7926727
  59. Gene therapy for cancer: what have we done and where are we going?
    J Natl Cancer Inst. 1997 Jan 1;89(1):21-39 PMID: 8978404
  60. Role of p53 in drug resistance in ovarian cancer.
    Lancet. 1997 Mar 15;349(9054):744-5 PMID: 9074569
  61. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain.
    Nat Med. 1997 Jun;3(6):632-8 PMID: 9176489
  62. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.
    Proc Natl Acad Sci U S A. 1996 May 14;93(10):4781-6 PMID: 8643480
  63. p53-mediated apoptosis in HeLa cells can be overcome by excess pRB.
    Oncogene. 1995 Apr 20;10(8):1563-71 PMID: 7731711
  64. p53; from inductive signal to cellular effect.
    Curr Opin Genet Dev. 1997 Feb;7(1):46-51 PMID: 9024633
  65. The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53?
    Bioessays. 1993 Oct;15(10):689-90 PMID: 7506024
  66. Regulation of apoptosis by viral gene products.
    J Virol. 1997 Mar;71(3):1739-46 PMID: 9032302
  67. Therapeutic targeting of the p53 tumor suppressor gene.
    Curr Opin Biotechnol. 1996 Dec;7(6):592-600 PMID: 8939636
  68. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression.
    Mol Cell Biol. 1995 Jun;15(6):3032-40 PMID: 7539102
  69. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells.
    Nat Med. 1996 May;2(5):574-7 PMID: 8616718
  70. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.
    J Exp Med. 1996 Apr 1;183(4):1357-65 PMID: 8666894
  71. Recruitment of p300/CBP in p53-dependent signal pathways.
    Cell. 1997 Jun 27;89(7):1175-84 PMID: 9215639
  72. p53 in signaling checkpoint arrest or apoptosis.
    Curr Opin Genet Dev. 1996 Feb;6(1):12-8 PMID: 8791489
  73. Identification of a p53-dependent negative response element in the bcl-2 gene.
    Cancer Res. 1994 Jun 15;54(12):3131-5 PMID: 8205530
  74. p53-mediated apoptosis: mechanisms and regulation.
    Behring Inst Mitt. 1996 Oct;(97):32-59 PMID: 8950466
  75. The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M.
    Mol Cell Biol. 1996 Jul;16(7):3884-92 PMID: 8668206
  76. The proto-oncogene Bcl-2 and its role in regulating apoptosis.
    Nat Med. 1997 Jun;3(6):614-20 PMID: 9176486
  77. Immunohistochemical detection of bcl-2 and p53 proteins and apoptosis in soft tissue sarcoma: their correlations with prognosis.
    Oncology. 1997 May-Jun;54(3):238-44 PMID: 9143406
  78. Failure to dephosphorylate retinoblastoma protein in drug-resistant cells.
    Cancer Res. 1995 Nov 15;55(22):5222-5 PMID: 7585579
  79. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.
    Cancer Res. 1994 Feb 1;54(3):794-9 PMID: 8306343
  80. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer.
    Nat Med. 1996 Sep;2(9):985-91 PMID: 8782455
  81. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway.
    Genes Dev. 1996 May 15;10(10):1219-32 PMID: 8675009
  82. p53: puzzle and paradigm.
    Genes Dev. 1996 May 1;10(9):1054-72 PMID: 8654922
  83. Role for c-Abl tyrosine kinase in growth arrest response to DNA damage.
    Nature. 1996 Jul 18;382(6588):272-4 PMID: 8717045
  84. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies.
    J Natl Cancer Inst. 1996 Oct 16;88(20):1442-55 PMID: 8841019
  85. The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products.
    EMBO J. 1996 Apr 1;15(7):1583-95 PMID: 8612582
  86. Dissection of the genetic programs of p53-mediated G1 growth arrest and apoptosis: blocking p53-induced apoptosis unmasks G1 arrest.
    Blood. 1995 May 15;85(10):2691-8 PMID: 7742528
  87. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies.
    Oncogene. 1996 Nov 7;13(9):1971-81 PMID: 8934544
  88. Wild-type p53 negatively regulates the expression of a microtubule-associated protein.
    Genes Dev. 1996 Dec 1;10(23):2971-80 PMID: 8956998
  89. P53 gene alterations in human tumors: perspectives for cancer control.
    Recent Results Cancer Res. 1997;143:369-89 PMID: 8912433
  90. Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells.
    Mol Cell Biol. 1993 Jan;13(1):711-9 PMID: 8417361
  91. The mdm-2 gene is induced in response to UV light in a p53-dependent manner.
    Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11623-7 PMID: 8265599
  92. Small peptides activate the latent sequence-specific DNA binding function of p53.
    Cell. 1995 Oct 20;83(2):237-45 PMID: 7585941
  93. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.
    Nat Med. 1997 Jun;3(6):639-45 PMID: 9176490
  94. Induction of apoptosis in HeLa cells by trans-activation-deficient p53.
    Genes Dev. 1995 Sep 1;9(17):2170-83 PMID: 7657168
  95. Complex formation between the lymphotropic papovavirus large tumor antigen and the tumor suppressor protein p53.
    J Virol. 1991 Oct;65(10):5417-24 PMID: 1895390
  96. Gas1-induced growth suppression requires a transactivation-independent p53 function.
    Mol Cell Biol. 1995 Dec;15(12):7152-60 PMID: 8524283
  97. Mdm2 promotes the rapid degradation of p53.
    Nature. 1997 May 15;387(6630):296-9 PMID: 9153395
  98. Viruses and apoptosis.
    Curr Opin Genet Dev. 1995 Feb;5(1):105-11 PMID: 7749317
  99. Cancer cell cycles.
    Science. 1996 Dec 6;274(5293):1672-7 PMID: 8939849
  100. A simple p53 functional assay for screening cell lines, blood, and tumors.
    Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3963-7 PMID: 7732013
  101. How phosphorylation regulates the activity of p53.
    J Mol Biol. 1996 Oct 25;263(2):103-13 PMID: 8913292
  102. The role of p53 as a transcription factor in the induction of apoptosis.
    Behring Inst Mitt. 1996 Oct;(97):60-71 PMID: 8950467
  103. A p53-dependent mouse spindle checkpoint.
    Science. 1995 Mar 3;267(5202):1353-6 PMID: 7871434
Article Info
Journal
Springer seminars in immunopathology
Abbr.
Springer Semin Immunopathol
ISSN
0344-4325
DOI
10.1007/BF00787230
Published
1998-00-00
Pages
345-62
Language
English
Region
Germany
NLM ID
7910384
Subset
IM
External Links
PubMed source DOI: 10.1007/BF00787230
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2